Can­cer case hos­pi­tal closes for in­ves­ti­ga­tion

China Daily (Canada) - - TOP NEWS - ByWANG XIAODONG wangx­i­aodong@ chi­

The mil­i­tary hos­pi­tal in­volved in a case in which a dying can­cer pa­tient ac­cused search en­gine gi­ant Baidu of pro­vid­ing mis­lead­ing med­i­cal treat­ment in­for­ma­tion sus­pended all its ser­vices on Wed­nes­day for a “thor­ough in­ves­ti­ga­tion”.

The Sec­ond Hos­pi­tal of the Bei­jing Armed Po­lice Corps said it will re­spond by Satur­day to re­quests from other pa­tients seek­ing com­pen­sa­tion, The Bei­jingNews re­ported.

“Due to the hos­pi­tal un­der­go­ing ed­u­ca­tion and rec­ti­fi­ca­tion, we will from to­day (Wed­nes­day) tem­po­rar­ily sus­pend all ex­ter­nal ser­vices,” the hos­pi­tal said in a no­tice. The ser­vices in­clude emer­gency care, out­pa­tient and in­pa­tient ser­vices.

The Peo­ple’s Armed Po­lice Force said it would co­op­er­ate fully with the in­ves­ti­ga­tion.

Ina brief state­ment re­leased on the Chi­nese mil­i­tary’s news web­site, the force said it paid great at­ten­tion to the case and had al­ready sent its own team to the hos­pi­tal.

Wei Zexi, a stu­dent at Xid­i­anUniver­sity inXi’an, Shaanxi prov­ince, died in early April af­ter re­ceiv­ing im­munother­apy treat­ment at the hos­pi­tal.

Ear­lier me­dia re­ports and somepa­tients claimed that the hos­pi­tal said in its pro­mo­tional ma­te­rial that the tech­niques it used for can­cer treat­ment came from Stan­ford School of Medicine in the United States.

Jana Chow, man­ager for me­dia re­la­tions at Stan­ford Health Care, said in an e-mail to China Daily on Wed­nes­day, “Stan­ford Health Care and Stan­ford School of Medicine have no con­nec­tion to this hos­pi­tal, or to this case.”

Becky Bach, Stan­ford School of Medicine’s me­dia spe­cial­ist, said that Stan­ford has never had any co­op­er­a­tion with any Chi­nese hos­pi­tal in the cel­lu­lar treat­ment sec­tor, in­clud­ing the hos­pi­tal in­volved in the case. She doesn’t un­der­stand why the hos­pi­tal em­pha­sized that the tech­niques were in­tro­duced from Stan­ford, ac­cord­ing to Caixin mag­a­zine’s WeChat ac­count.

Wei­was­di­ag­nosed with syn­ovial sar­coma, a rare, of­ten tern­i­mal can­cer of the soft tis­sue, in 2014 and his par­ents sent him to the hos­pi­tal last year af­ter learn­ing on Baidu that the im­munother­apy used there had been de­vel­oped at Stan­ford and was very ef­fec­tive.

Wei dis­closed this in an on­line post in Fe­bru­ary, two months be­fore he died.

Fam­i­lies and rel­a­tives of pa­tients who have re­ceived or are re­ceiv­ing sim­i­lar treat­ment said they turned to the hos­pi­tal af­ter learn­ing from web­sites or news­pa­pers that the ther­apy is ef­fec­tive and had been in­tro­duced from the US.

Ac­cord­ing to de­scrip­tions on Baidu of the ther­apy used by the hos­pi­tal, it treats dis­eases by ex­tract­ing im­mune cells from pa­tients, re­pro­duc­ing large num­bers of them that are re-in­jected into the pa­tient to kill a dis­ease or virus.

Fam­i­lies and rel­a­tives of pa­tients re­ceiv­ing the ther­apy at the hos­pi­tal con­firmed the de­scrip­tions.

The web­site of Stan­ford School of Medicine states that the school has im­munother­apy pro­grams, but the re­search is still at the clin­i­cal trial stage.

Newspapers in English

Newspapers from China

© PressReader. All rights reserved.